managing-pain-management-protocols

# Managing Pain Management Protocols

Structures multimodal pain management with non-opioid-first approaches, WHO analgesic ladder application, and patient-controlled analgesia protocols.

## Why This Skill Exists

Pain is the most common reason patients seek medical care, yet its management remains one of healthcare's greatest challenges. The dual imperatives of adequate analgesia and opioid stewardship require pharmacists to design multimodal regimens that maximize non-opioid therapies before escalating to opioids. The 2022 CDC Clinical Practice Guideline for Prescribing Opioids emphasizes non-pharmacologic and non-opioid pharmacologic therapy as first-line for most pain conditions.

The WHO analgesic ladder—originally developed for cancer pain—provides a three-step framework that remains foundational for pain management: non-opioid analgesics (Step 1), weak opioids for mild-moderate pain (Step 2), and strong opioids for severe pain (Step 3). Modern multimodal analgesia extends this concept by combining agents with different mechanisms (NSAIDs, acetaminophen, gabapentinoids, regional anesthesia, ketamine) to achieve synergistic pain relief while minimizing opioid exposure. Patient-controlled analgesia (PCA) requires precise pharmacist-verified programming—PCA pump errors account for a significant proportion of opioid-related adverse events reported to the ISMP. Pharmacists play a central role in selecting agents, dosing, monitoring, and tapering pain regimens across acute, chronic, and palliative settings.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the pain type (acute surgical, acute medical, chronic non-cancer, cancer/palliative, neuropathic)? (Default: classify)
2. What is the current pain severity (NRS 0-10, functional assessment)? (Default: obtain pain assessment)
3. Is the patient opioid-naive or opioid-tolerant? (Default: determine—opioid-tolerant = ≥60 mg OME/day for ≥1 week)
4. What is the patient's renal and hepatic function? (Default: check labs for analgesic dosing)
5. What non-opioid therapies have been tried or are currently in use? (Default: review active orders)
6. Is the patient a candidate for regional anesthesia or nerve blocks? (Default: assess with anesthesiology)
7. What is the patient's opioid risk assessment (ORT, history of substance use disorder)? (Default: screen)
8. Is PCA being considered? If so, what are the patient's cognitive and physical requirements for self-administration? (Default: assess suitability)

### Documents to Request

- Pain assessment documentation (NRS score, location, quality, temporal pattern)
- Current analgesic orders with doses, frequencies, and PRN utilization patterns
- Surgical/procedural details (type, expected pain duration and intensity)
- Opioid history (chronic use, prior prescriptions, PDMP query)
- Renal function (SCr, CrCl) and hepatic function (LFTs)
- Allergy and ADR history (specific to analgesics: NSAIDs, opioids, local anesthetics)
- Substance use history and opioid risk assessment tool scores
- Functional goals (target pain level for mobilization, PT participation)

---

## Step 1: Apply the WHO Analgesic Ladder and Multimodal Framework

**WHO Three-Step Analgesic Ladder:**

| Step | Pain Severity | Agents | Adjuvants |
|---|---|---|---|
| Step 1 | Mild (NRS 1-3) | Acetaminophen, NSAIDs | ± adjuvants based on pain type |
| Step 2 | Moderate (NRS 4-6) | Weak opioids (tramadol, codeine) + Step 1 agents | ± adjuvants |
| Step 3 | Severe (NRS 7-10) | Strong opioids (morphine, hydromorphone, fentanyl) + Step 1 agents | ± adjuvants |

**Modern multimodal approach (layer non-opioid agents first):**

| Agent Class | Mechanism | Role | Key Considerations |
|---|---|---|---|
| Acetaminophen | Central COX inhibition, descending pathways | Foundational; scheduled, not PRN | ≤4 g/day (≤2 g/day hepatic impairment); IV available for NPO |
| NSAIDs (ketorolac, ibuprofen, celecoxib) | COX-1/COX-2 inhibition | Moderate-severe pain; anti-inflammatory | Ketorolac ≤5 days; avoid in CKD, GI bleed risk, cardiovascular risk |
| Gabapentinoids (gabapentin, pregabalin) | α2δ calcium channel modulation | Neuropathic pain, perioperative anxiety reduction | Renal dose adjustment; sedation/respiratory depression additive with opioids |
| Ketamine (sub-anesthetic) | NMDA receptor antagonist | Opioid-tolerant patients, opioid-sparing adjunct | 0.1-0.3 mg/kg/h infusion; avoid in psychosis, uncontrolled HTN |
| Lidocaine (IV) | Sodium channel blockade | Visceral/abdominal pain, opioid-sparing | 1-1.5 mg/kg/h infusion; cardiac monitoring required |
| Muscle relaxants (cyclobenzaprine, methocarbamol) | Central muscle relaxation | Musculoskeletal spasm component | Sedation additive with opioids; avoid cyclobenzaprine in elderly |
| Topical agents (lidocaine patch, diclofenac gel, capsaicin) | Local action | Localized pain, reduces systemic exposure | Minimal systemic absorption; good safety profile |
| Regional anesthesia (nerve blocks, epidural) | Local anesthetic neural blockade | Surgical pain, rib fractures, limb injuries | Anesthesiology collaboration; superior opioid-sparing |

---

## Step 2: Opioid Selection and Dosing (When Indicated)

**Opioid-naive patients (acute pain):**

| Opioid | Starting Dose (oral) | Starting Dose (IV) | Interval | Notes |
|---|---|---|---|---|
| Morphine | 5-10 mg q4h PRN | 2-4 mg q3-4h PRN | q3-4h | Avoid in CrCl <30 (M6G accumulation) |
| Oxycodone | 5-10 mg q4-6h PRN | N/A (US) | q4-6h | No active metabolites; hepatic metabolism |
| Hydromorphone | 2-4 mg q4-6h PRN | 0.5-1 mg q3-4h PRN | q3-4h | Better in renal impairment than morphine |
| Hydrocodone | 5-10 mg q4-6h PRN | N/A | q4-6h | Available in combination products |
| Tramadol | 50-100 mg q4-6h PRN | N/A (US) | q4-6h | Seizure risk; serotonin syndrome risk; CYP2D6 dependent |

**Key dosing principles:**
- Start low, titrate to effect
- Use immediate-release formulations for acute pain; never initiate ER/LA in opioid-naive patients
- Maximum tramadol: 400 mg/day (300 mg/day if age >75)
- Avoid meperidine (normeperidine accumulation → seizures; no role in modern pain management)
- Avoid codeine in CYP2D6 ultra-rapid metabolizers (fatal respiratory depression reported)
- Codeine contraindicated in children <12 years and post-tonsillectomy in children <18

---

## Step 3: Patient-Controlled Analgesia (PCA) Protocol

**PCA eligibility criteria:**
- Patient can understand PCA concept and self-administer (press button)
- Patient is alert enough to make dosing decisions
- No authorized agent dosing (family/nurse pressing button = unauthorized, unsafe)
- Appropriate for moderate-severe pain expected to last >24 hours (post-surgical, sickle cell crisis)

**Standard PCA programming (opioid-naive adult):**

| Parameter | Morphine PCA | Hydromorphone PCA | Fentanyl PCA |
|---|---|---|---|
| Concentration | 1 mg/mL | 0.2 mg/mL | 10 mcg/mL |
| Demand dose | 1-2 mg | 0.2-0.4 mg | 20-50 mcg |
| Lockout interval | 6-10 min | 6-10 min | 6-10 min |
| 1-hour limit | 10 mg | 2 mg | 300 mcg |
| Continuous (basal) rate | 0 (not recommended opioid-naive) | 0 | 0 |
| Loading dose (optional) | 2-5 mg IV (clinician bolus) | 0.4-1 mg IV | 50-100 mcg IV |

**Critical PCA safety requirements:**
- Continuous pulse oximetry and/or capnography for all PCA patients
- Pasero Opioid-Induced Sedation Scale (POSS) assessment q1-2h
- Naloxone 0.4 mg IV at bedside (accessible to nursing)
- Independent double-check of PCA programming by two nurses before initiation
- Basal rate NOT recommended for opioid-naive patients (increased respiratory depression risk)
- PCA by proxy (family-controlled) is prohibited except in specific institutional protocols with safeguards

---

## Step 4: Monitoring and Opioid Safety

**Monitoring parameters:**

| Parameter | Frequency | Action Threshold |
|---|---|---|
| Pain score (NRS 0-10) | q4h and with each PRN dose | Reassess regimen if NRS >4 despite multimodal therapy |
| Sedation scale (POSS) | q1-2h for PCA; q4h for intermittent opioids | POSS ≥3 (somnolent): hold opioid, assess airway, consider naloxone |
| Respiratory rate | q1-2h for PCA; q4h for IV; q4-8h for oral | <10/min: hold opioid, stimulate, naloxone if needed |
| Oxygen saturation | Continuous for PCA; q4h for others | <92%: assess, supplemental O2, consider dose reduction |
| Bowel function | Daily | Initiate bowel regimen with opioid start (senna + docusate) |
| Nausea/vomiting | With pain assessments | Ondansetron 4 mg IV PRN; consider opioid rotation if persistent |
| Functional status | Daily | Document ability to mobilize, participate in PT, perform ADLs |

**Naloxone dosing for opioid-induced respiratory depression:**
- Mild-moderate (RR 8-10, responsive to stimulation): Dilute naloxone 0.4 mg in 10 mL NS; give 1 mL (0.04 mg) IV q2-3 min until RR >12
- Severe (RR <8, unresponsive): Naloxone 0.4 mg IV bolus; repeat q2-3 min; consider infusion (2/3 of response dose per hour)
- Duration: Naloxone half-life (30-90 min) is shorter than most opioids; monitor for re-sedation

---

## Step 5: Opioid Tapering and Transition

**Acute pain opioid taper (post-surgical):**
- Reduce opioid by 25-50% per day as pain improves and non-opioid agents provide adequate relief
- Convert IV to oral when patient meets conversion criteria
- Target opioid discontinuation by post-operative day 3-5 for most surgeries
- At discharge, prescribe the minimum quantity needed (3-7 days typical)

**Discharge prescribing principles per CDC guidelines:**
- Prescribe lowest effective dose of immediate-release opioid
- Limit initial supply to 3-7 days for acute pain
- Counsel on safe storage and disposal (drug take-back, disposal pouches)
- Co-prescribe naloxone if ≥50 MME/day or concurrent benzodiazepine
- Document pain management follow-up plan

**Chronic opioid taper (when indicated):**
- Reduce by 10% of total daily dose per week (slow taper)
- Reduce by 10% per month for long-term high-dose therapy
- Collaborate with pain management and addiction medicine
- Monitor for withdrawal symptoms (COWS scale) and provide symptomatic management

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. Were non-opioid therapies optimized before initiating or escalating opioids?
2. Is the selected opioid dose appropriate for opioid-naive vs. opioid-tolerant status?
3. Is PCA programming verified with independent double-check and appropriate safety monitoring?
4. Are opioid monitoring parameters (sedation, respiratory rate, O2 sat) ordered with appropriate frequency?
5. Is a taper/discontinuation plan documented for acute pain patients?

---

## Quality Audit

- [ ] Pain type classified (acute, chronic, neuropathic, cancer) and assessed with validated tool
- [ ] Multimodal non-opioid agents initiated before or concurrently with opioids
- [ ] Acetaminophen and/or NSAID scheduled (not PRN) as foundational agents
- [ ] Opioid selected appropriately for organ function (avoid morphine in renal failure)
- [ ] Opioid-naive patients started on immediate-release formulations at lowest effective dose
- [ ] PCA programming independently double-checked by two clinicians
- [ ] Basal rate NOT used for opioid-naive PCA patients
- [ ] Continuous monitoring ordered for PCA patients (pulse oximetry, sedation scale)
- [ ] Naloxone available at bedside for all opioid-receiving patients
- [ ] Bowel regimen initiated with opioid start (senna + docusate prophylaxis)
- [ ] MME/day calculated and CDC thresholds applied (50 MME, 90 MME triggers)
- [ ] PDMP queried for patients receiving opioid prescriptions at discharge
- [ ] Discharge opioid quantity limited to 3-7 days with disposal instructions
- [ ] Taper plan documented for patients expected to discontinue opioids
- [ ] Functional goals documented (not just pain score targets)

---

## Guidelines

- Multimodal analgesia is the standard of care: always optimize non-opioid agents before escalating to opioids
- The WHO analgesic ladder remains valid as a framework; apply it bidirectionally (step up for increasing pain, step down as pain resolves)
- PCA by proxy (family members pressing the button) is unsafe and prohibited in standard practice; only the patient should activate doses
- Never initiate extended-release or long-acting opioids in opioid-naive patients (FDA black box warning)
- Meperidine has no role in modern pain management; normeperidine accumulation causes seizures
- Functional goals (ability to mobilize, participate in PT) are more meaningful outcome measures than pain scores alone
- Co-prescribe naloxone for patients at elevated overdose risk: ≥50 MME/day, concurrent benzodiazepines, history of overdose, substance use disorder
- Pain management is iterative: reassess, adjust, and document at every clinical encounter